HUP0202895A2 - Eljárás késleltetett hatóanyag-leadású komplexek előállítására - Google Patents

Eljárás késleltetett hatóanyag-leadású komplexek előállítására

Info

Publication number
HUP0202895A2
HUP0202895A2 HU0202895A HUP0202895A HUP0202895A2 HU P0202895 A2 HUP0202895 A2 HU P0202895A2 HU 0202895 A HU0202895 A HU 0202895A HU P0202895 A HUP0202895 A HU P0202895A HU P0202895 A2 HUP0202895 A2 HU P0202895A2
Authority
HU
Hungary
Prior art keywords
make
sustained release
release formulation
lgt
formula
Prior art date
Application number
HU0202895A
Other languages
English (en)
Inventor
Thomas Ciarán Loughman
Original Assignee
Kinerton Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinerton Limited filed Critical Kinerton Limited
Publication of HUP0202895A2 publication Critical patent/HUP0202895A2/hu
Publication of HUP0202895A3 publication Critical patent/HUP0202895A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Peptides Or Proteins (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)

Abstract

A találmány tárgya eljárás késleltetett hatóanyag-leadású komplexek,előállítására, amelyek (A) képletű szomatosztatin-származékot és egykopolimert tartalmaznak, ahol a kopolimer egy poli-(L)-tejsav-glikolsav-borkősavat, (P(L)LGT ) tartalmaz, és a komplexben az (A)képletű vegyület ionosan kapcsolódik a P(L)LGT karboxicsoportjaihoz. Atalálmány tárgyához tartozik a fenti komplexek mikrorészecskéinekelőállítása is. Ó
HU0202895A 1999-08-18 2000-08-14 Process to make a sustained release formulation HUP0202895A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE19990700A IES990700A2 (en) 1999-08-18 1999-08-18 Process to make a sustained release formulation
PCT/IE2000/000099 WO2001012232A2 (en) 1999-08-18 2000-08-14 Process to make a sustained release formulation

Publications (2)

Publication Number Publication Date
HUP0202895A2 true HUP0202895A2 (hu) 2003-02-28
HUP0202895A3 HUP0202895A3 (en) 2003-11-28

Family

ID=11042112

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202895A HUP0202895A3 (en) 1999-08-18 2000-08-14 Process to make a sustained release formulation

Country Status (26)

Country Link
US (1) US6893645B1 (hu)
EP (1) EP1212095B1 (hu)
JP (1) JP3730917B2 (hu)
CN (2) CN1246040C (hu)
AR (1) AR022647A1 (hu)
AT (1) ATE243044T1 (hu)
AU (1) AU755229B2 (hu)
BR (1) BR0013349A (hu)
CA (1) CA2380902C (hu)
CZ (1) CZ294433B6 (hu)
DE (1) DE60003438T2 (hu)
DK (1) DK1212095T3 (hu)
ES (1) ES2195925T3 (hu)
HK (1) HK1044285A1 (hu)
HU (1) HUP0202895A3 (hu)
IE (1) IES990700A2 (hu)
IL (1) IL148044A0 (hu)
MX (1) MXPA02001415A (hu)
NO (1) NO20020762L (hu)
NZ (1) NZ517251A (hu)
PL (1) PL199862B1 (hu)
PT (1) PT1212095E (hu)
RU (1) RU2211694C1 (hu)
TW (1) TWI230069B (hu)
WO (1) WO2001012232A2 (hu)
ZA (1) ZA200202027B (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1348444B1 (en) * 1999-08-18 2006-04-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Sustained release formulation of a peptide complexed with a polymer
DK1204429T3 (da) * 1999-08-18 2004-03-08 Sod Conseils Rech Applic Præparat til forsinket frigivelse af et peptid
US7109166B1 (en) 1999-08-18 2006-09-19 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Sustained release formulation of a peptide
JP5183068B2 (ja) * 2003-12-22 2013-04-17 フィンレイ，ウォーレン，エイチ 大気噴出凍結乾燥法による粉末形成
KR101150242B1 (ko) 2004-10-27 2012-06-13 유니버시티 오브 덴버 부신피질 자극 호르몬 유사체 및 관련 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK74495A3 (en) 1993-01-06 1997-01-08 Kinerton Ltd Ionic molecular conjugates of biodegradable polyesters with bioactive polypeptides and a method of preparation thereof
US5863985A (en) * 1995-06-29 1999-01-26 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6221958B1 (en) * 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
KR100325972B1 (ko) * 1993-08-09 2002-07-27 바이오메져 인코퍼레이티드 치료성펩타이드유도체
IE960308A1 (en) 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate
WO1998008528A1 (en) * 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
US5972893A (en) * 1997-05-06 1999-10-26 Cedars-Sinai Medical Center Method of treating hyperprolactinemia and prolactinomas
AR014069A1 (es) * 1998-01-29 2001-01-31 Kinerton Ltd Procedimiento para preparar microparticula o microparticulas unidas encapsuladas
WO2000012232A1 (fr) 1998-08-28 2000-03-09 Mitutoyo Corporation Laveuse automatique de pieces pour intervention prealable dans un systeme de mesure et de production automatique equipe de ladite laveuse
DK1204429T3 (da) 1999-08-18 2004-03-08 Sod Conseils Rech Applic Præparat til forsinket frigivelse af et peptid

Also Published As

Publication number Publication date
NZ517251A (en) 2003-08-29
ATE243044T1 (de) 2003-07-15
AU755229B2 (en) 2002-12-05
CA2380902C (en) 2008-08-05
AR022647A1 (es) 2002-09-04
HUP0202895A3 (en) 2003-11-28
NO20020762L (no) 2002-04-16
CZ2002266A3 (cs) 2002-05-15
WO2001012232A2 (en) 2001-02-22
DE60003438D1 (de) 2003-07-24
NO20020762D0 (no) 2002-02-15
DK1212095T3 (da) 2003-10-06
EP1212095B1 (en) 2003-06-18
ZA200202027B (en) 2002-12-24
CN1377283A (zh) 2002-10-30
PL354263A1 (en) 2003-12-29
RU2002106809A (ru) 2004-01-20
WO2001012232A8 (en) 2002-06-06
JP3730917B2 (ja) 2006-01-05
HK1044285A1 (en) 2002-10-18
ES2195925T3 (es) 2003-12-16
IL148044A0 (en) 2002-09-12
PT1212095E (pt) 2003-10-31
JP2003507346A (ja) 2003-02-25
US6893645B1 (en) 2005-05-17
CN1246040C (zh) 2006-03-22
CN1823736A (zh) 2006-08-30
RU2211694C1 (ru) 2003-09-10
MXPA02001415A (es) 2002-08-12
EP1212095A2 (en) 2002-06-12
BR0013349A (pt) 2002-04-23
AU6464700A (en) 2001-03-13
CA2380902A1 (en) 2001-02-22
WO2001012232A3 (en) 2002-04-04
PL199862B1 (pl) 2008-11-28
DE60003438T2 (de) 2004-05-06
CZ294433B6 (cs) 2005-01-12
TWI230069B (en) 2005-04-01
IES990700A2 (en) 2001-08-22

Similar Documents

Publication Publication Date Title
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
HUP0203060A2 (hu) Késleltetett hatóanyag-leadású peptidkomplex, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmény
CA2303498A1 (en) Dioxocyclopentyl hydroxamic acids
TR200103474T2 (tr) Bileşimlerin anti-bakteriyel madde olarak yeni kullanımları
TR200102910T2 (tr) èeker artìklarìyla ikame edilmiç 1,4-benzotiyazepin-1,1-dioksid trevleri
AU5681800A (en) Quinoline derivatives as antibacterials
NO20015226L (no) Tri-aryl syrederivater som PPAR reseptor ligander, farmasoytisk sammensetning omfattende samme og anvendelse av samme for fremstilling av medikament.
HUP0100221A2 (hu) Nyújtott hatású készítmény és eljárás az előállítására, valamint alkalmazása
MY129350A (en) Aripiprazole oral solution
HUP0401647A2 (hu) Új béta-fenil-alfa-oxi-propionsav-származékok, előállítási eljárásaik és gyógyszerészetileg fontos vegyületek előállításánál történő felhasználásuk
CA2445145A1 (en) Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes
CA2446944A1 (en) Anti-inflammatory and immunomodulatory amino acid derivatives, their preparation and use
HUP0200895A3 (en) Benzimidazole derivatives of alpha-substituted carboxylic acids, pharmaceutical compositions containing them and their use
DK1086124T3 (da) Nye cyclosporiner
ATE429416T1 (de) Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen
HUP9702345A2 (hu) 3-Hidroxi-piridin-2-karbonsav-amid-észter-származékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NO20044767L (no) Farmasoytisk formulering med modifisert frigjoring
HUP0202880A2 (hu) Nyújtott felszabadulású készítmények, eljárás előállításukra és alkalmazásuk
MXPA03011954A (es) Nuevos derivados de acido sulfonico.
HUP0300972A2 (hu) Gatifloxacin-pentahidrát
HUP0202895A2 (hu) Eljárás késleltetett hatóanyag-leadású komplexek előállítására
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
MXPA02004441A (es) Derivados de isoxazol como inhibidores de la fosfodiesterasa.
ATE344237T1 (de) Hydroxyacetamidobenzolsulfonamidderivate
NO20021727L (no) Fremgangsmåte for fremstilling av 3,4-metylen-dioksy- mandelisk syre

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees